<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536458</url>
  </required_header>
  <id_info>
    <org_study_id>01 02</org_study_id>
    <secondary_id>GOELAMS 01 02</secondary_id>
    <secondary_id>GOELNH LOGLOC</secondary_id>
    <nct_id>NCT00536458</nct_id>
  </id_info>
  <brief_title>Treatment of Localized Low Grade Lymphomas</brief_title>
  <official_title>Phase III Study of Treatment of Localized Lymphomas: Radiotherapy Versus Radio-Chemotherapie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare localiezd radiotherapy to localized radiotherapy followed by 6 cycles of
      chemotherapy in the treatment of localiezd low grade lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment ol localized low grade lymphomas is Radiotherapy alone can offer long
      term remissions to some patients .

      No study have clearly demonstrated the interest of chemotherapy. The purpose of the study is
      to determine wether prednisone administrated after first line local radiotherapy (30 GY) can
      pre in the treatment of localized low grade lymphomas of adult patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>failure free survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rates at the end of the treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognstic value of molecular analyses in blood and marrow</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Lymphoma, Low-Grade</condition>
  <arm_group>
    <arm_group_label>radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>minichep + radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MINI CHEP</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>mini chep+ radiotherapy</description>
    <arm_group_label>radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MINI CHEP</intervention_name>
    <description>chemotherapy minichep 6 courses</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low grade lymphoma defined according to the Ann Arbor classification

          -  localized

        Exclusion Criteria:

          -  Subjects unable to signed informed consent

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>eric DECONINCK, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional university hospital</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2007</study_first_submitted>
  <study_first_submitted_qc>September 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2007</study_first_posted>
  <last_update_submitted>October 31, 2007</last_update_submitted>
  <last_update_submitted_qc>October 31, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2007</last_update_posted>
  <keyword>localized low grade lymphoma</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Molecular analyses</keyword>
  <keyword>primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

